Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021
Vaxart, a clinical-stage biotechnology company, will host a conference call and business update on March 2, 2021, at 4:30 PM ET. The company specializes in developing oral recombinant vaccines that are tablet-administered rather than injected. Vaxart aims to create vaccines for various diseases, including coronavirus, Norovirus, and seasonal influenza, using a proprietary delivery platform that eliminates the need for refrigeration. This innovative approach also reduces the risk of needle-stick injuries.
- Development of oral vaccines for diverse diseases, potentially broadening market reach.
- Proprietary delivery platform enhances vaccine storage and shipment flexibility.
- Clinical-stage status may lead to uncertainties in product development timelines.
- Dependence on successful trials to commercialize vaccine candidates.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021.
| Conference Call Dial-In & Webcast Information: | |
| Date: | Tuesday, March 2, 2021 |
| Time: | 4:30 PM Eastern Time |
| Domestic: | 877-407-0784 |
| International: | 201-689-8560 |
| Conference ID: | 13716984 |
| Webcast: | http://public.viavid.com/index.php?id=143739 |
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
| Contacts | |
| Brant Biehn Vaxart, Inc. 650 550 3500 IR@vaxart.com | Joyce Allaire LifeSci Advisors, LLC 617 435 6602 jallaire@lifesciadvisors.com |
FAQ
When is Vaxart's business update conference call?
What are Vaxart's main vaccine candidates?
How does Vaxart's vaccine delivery platform work?
What is the significance of Vaxart's proprietary technology?
What is Vaxart's stock symbol?
